Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model
Alexander M.M. Eggermont(University Medical Center Utrecht), Alexander Meves(Mayo Clinic), Charles Perniciaro, Jvalini Dwarkasing, Félicia Tjien-Fooh, Domenico Bellomo, Renske Wever, Mark A. Cappel(Jacksonville College), Julia S. Lehman(Mayo Clinic), Alina G. Bridges(Mayo Clinic in Arizona), Martin H. van Vliet, Tina J. Hieken(Mayo Clinic), James W. Jakub(Mayo Clinic in Arizona), Enrica Quattrocchi(Mayo Clinic in Arizona), Mark R. Pittelkow(Mayo Clinic in Arizona), Suzette M. Arias‐Mejias(Mayo Clinic in Arizona), Sindhuja Sominidi‐Damodaran(Mayo Clinic in Arizona), Sanjay P. Bagaria(WinnMed), Barbara Rentroia‐Pacheco(Erasmus MC Cancer Institute), Jason C. Sluzevich(WinnMed), Dennis H. Murphree(Mayo Clinic in Arizona)
Cited by 49
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k